ABT-492 MegluMine

ABT-492 MegluMine Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials.

• Verwenden

  Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa.

• Biologische Aktivität

  Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine is a broad spectrum fluoroquinolone antibiotic. Delafloxacin has a wide range of activity against drug-resistant Staphylococcus aureus, Streptococcus pneumoniae and Klebsiella pneumoniae.

ABT-492 MegluMine Upstream-Materialien And Downstream Produkte

ABT-492 MegluMine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(124)Suppliers